OUr team

Dr. William Schwieterman joined Stream Biomedical in 2020 and has been on

the board of directors of Stream since its inception. A Board-certified internist

and a rheumatologist who previously oversaw the development and approval of

numerous investigational drugs while a supervisor at the Food and Drug

Administration (FDA), including Enbrel®, Re1nicade®, Humira®, Synagis®,

and others, he brings extensive biopharmaceutical experience to his role, notably

in the area of clinical development and regulatory science.

Since leaving FDA Dr. Schwietern1an has worked extensively for and within

many companies in the pharmaceutical industry. His work includes roles as

Chief Medical Officer for Chelsea Therapeutics (2009-2014), a Charlotte, North

Carolina based-company acquired by Lundbeck Inc. for $6.58 million following

the approval of its drug droxidopa for the treatment of neurogenic orthostatic

hypotension, and as CEO for Mateon Therapeutics (2015-2019) -- a South San

Francisco-based company that merged with Oncotelic Inc. during his tenure.

Dr. Schwieterman has extensive experience as a member of various scientific

advisory, boards, boards of directors, and on Wall Street as a long-time

consultant and analyst for Perceptive Advisors, a New York City-based hedge

fund specializing in health care stocks. Dr. Schwieterrnan obtained his M.D.

from the University of Cincinnati College of Medicine, performed his residency

at Mt. Sinai Hospital in New York City, and completed two postgraduate

fellowships at the National Institutes of Health.

H. Davis Adkisson, Ph.D., Chief Scientific Officer, joined Stream Biomedical in

2018, bringing two decades in industry experience and academic research.

Prior co Stream, Dr. Adkisson served as Chief Scientific Officer at ISTO Biologics,

a regenerative medicine company formed in 2016 from the merger of ISTO

Technologies and Arteriocyte. A recognized leader in autologous stem cell

therapies, the combined portfolio offered evidence-based biologic solutions

dedicated to helping patients heal faster for spine, orthopedic, and wound healing

application. Dr. Adkisson is co-founder and former Chief Scientific Officer, lsto

Technologies (established in 1998), a pioneer in allogeneic tissue and cultured cell-based

tissue engineered solutions for joint resurfacing and spinal care. Dr Adkisson

led a team of researchers that successfully advanced two cell therapies to late-stage

clinical trials, work that originated from discoveries made during his postdoctoral

fellowship at Washington University in St Lou.is. Davis additionally oversaw preclinical

development and 510K clearance of a novel bone graft substitute (InQu)

supporting endochondral bone growth through timed release of hyaluronic acid

that was commercialized in 2008. The lnQu product line continues to be utilized to

treat bony defects in orthopedic trauma, sports medicine, and variety of fusion

procedures, predominantly ortho/neuro spine and foot & ankle. Dr. Adkisson,

recognized as a leading expert in cartilage and bone biology, has authored or coauthored

28 scientific articles and book chapters and holds >20 US and

International patents. Dr Adkisson graduated from the College of Charleston with

a B.S. in chemistry and completed his Ph.D. in biochemistry from the University of

South Carolina. He completed his postdoctoral training at Washington

University, School of Medicine, Division of Rheumatology. In addition,

Dr. Adkisson is the 2008 recipient of the Distinguished Alumnus Award

from the College of Charleston.

Bryan Clossen, Ph.D., Director of Translational Programs, joined Stream Biomedical

in 2018, and has been central in the preclinical development of rhPDVLG3, both

internal studies and in designing and managing collaborations with multiple academic

and CRO laboratories. During his doctoral training at Texas A&M Health Science

Center, Dr. Clossen's academic re.search focused on improving translational models

of neurodegenerative disorders, particularly those present with potential

neuroendoc1ine or sex-differences in clinical pathology. Critically, this work

generated data supporting extransynaptic GABBAergic inhibitory signaling and

neurosteroid-based therapy as a viable therapeutic target for pharmacoresistant

hyperexcitability disorders. The recently approved Zulresso (Brexanolone) is a prime

example of this new class of therapeutic. This research experience encompassed a

wide range of preclinical models and included novel and combination approaches

involving tandem EEG-implantation in models of traumatic brain injury, epilepsy,

and stroke.

Upon joining Stream, Dr. Clossen leveraged his translational modeling and drug screening

experience to accelerate Stream's research into Perlecan Domain V-based

protein therapeutics, eventually leading to the identification and selection of

rhPDVLG3 as Stream's lead therapeutic candidate. He has authored or co-authored

10 scientific articles and serves as a reviewer for multiple peer-reviewed journals. He

holds a B.S. in Molecular and Experimental Nutrition from Texas A&M, and a Ph.D.

from Texas A&M Institute for Neuroscience, working in the Neuroscience

and Experimental Therapeutics Department of the Texas A&M College of Medicine.

Seth Fisher joined Stream Biomedical in 2023 as a Sr. Process Engineer.

Dr. Fisher has over 30 years of experience in the biopharmaceutical

industry from discovery of protein therapeutics, through process

development toclinical manufacturing of protein therapeutics with 14

years in a GMP environment. He has transferred numerous processes

from process development into a clinical manufacturing setting for

IND enabling studies. During his time working in discovery, he was

involved in the discovery and characterization of multiple enzymes for

use as therapeutic targets as well as the production of peptibodics

(peptide-PC fusion) directed to myostatin receptor that eventually was

tested in a FIH Phase 1 clinical study. Mr. Fisher holds a BA in

Philosophy from Boston University.